Ever since Reichlin et al. [1] published their article entitled “Incremental value of copeptin for rapid rule-out of acute myocardial infarction” in 2009, the concept of a single, combined troponin and copeptin test at admission in patients with suspected acute coronary syndrome (ACS) has been tested and reported in an increasing number of publications, with conflicting results and conclusions. Here, AVP is linked to myocardial infarction.